|
Crooke did mention in the January stock-line.com interview that, and I'm paraphrasing, that while the company had cash in the bank sufficient to get the job done, that they might turn to the equity market sometime in the near future to raise additional cash. We didn't have long to wait. IMO, Crooke, in the interview, was optimistic about the future, stating that the "bulk of the technology risk was behind us", and that all drugs in the clinical pipeline were showing efficacy without limiting side-effects. He described 2302 as having remarkable positive effects with no side effects and no patient withdrawls. May the $50 mil from this offering help bring 2302, 3521, 5132, and the others successfully to market. That's the payoff. A revenue stream from anti-virals, anti-inflammatories, anti-Ca's, drug discovery and target validation collaborations, etc., that proves that the $50 mil worth of dilution was money well spent. |
